From: Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India
Study | Â | Subjects enrolled (N) | Pvmdr1 haplotypesa | Microsatellite genotyping | |||||
---|---|---|---|---|---|---|---|---|---|
Isolates successfully genotyped (n) | 958M/Y976/1076L (n (%)) | 958M/Y976/F1076 (n (%)) | Isolates successfully genotyped (n) | Multiclonal infections (n (%)) | Clones (n) | Multiplicity of infectionc | |||
in vivo therapeutic efficacy: | Â | Â | Â | Â | Â | Â | Â | ||
 | Day 0 | 125 | 33 | 33 (100) | 0 (0.0) | 33 | 5 (15.2) | 38 | 1.15 |
 | Day 3 | 19 | 0 | - | - | 0 | - | - | - |
 | Day Other | 17 | 15 | 14 (93.3) | 1 (6.7) | 17 | 3b (17.6) | 21 | 1.24 |
 | Total | 125 | 48 | 47 (97.9) | 1 (2.1) | 50 | 8 (16.0) | 59 | 1.18 |
in vitro drug assay: | Â | Â | Â | Â | Â | Â | Â | ||
 | Group 1 | 51 | 9 | 8 (88.9) | 1 (11.1) | 10 | 4 (40.0) | 14 | 1.40 |
 | Group 2 | 17 | 9 | 9 (100) | 0 (0.0) | 10 | 2 (20.0) | 12 | 1.20 |
 | Total | 68 | 18 | 17 (94.4) | 1 (5.6) | 20 | 6 (30.0) | 26 | 1.30 |